Future directions in haploidentical hematopoietic stem cell transplantation

References

• Bolon YT, Atshan R, Allbee-Johnson ME-MN, et al. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides; 2022.
   Google Scholar
• Bolaños-Meade J, Hamadani M, Wu J, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338–2348. doi:10.1056/NEJMoa2215943
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Cao K, Fernandez-Vina M, et al. The European society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(5):521–534. doi:10.1038/s41409-017-0062-8
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Horowitz M, Schreiber H, Elder A, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018;53(11):1379–1389. doi:10.1038/s41409-018-0171-z
   PubMed Web of Science ®Google Scholar
• DeZern AE, Franklin C, Tsai HL, et al. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021;5(5):1360–1368. doi:10.1182/bloodadvances.2020003922
   PubMed Web of Science ®Google Scholar
• Saliba RM, Kanakry CG, Gadalla S, et al. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2024;99(1):38–47. doi:10.1002/ajh.27126
   Web of Science ®Google Scholar
• Zou J, Kongtim P, Srour SA, et al. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol. 2022;13:1033871. doi:10.3389/fimmu.2022.1033871
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498. doi:10.1056/NEJMoa1408617
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Shah MV, Saliba RM, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24(6):1232–1236. doi:10.1016/j.bbmt.2017.09.005
   PubMed Web of Science ®Google Scholar
• Canaani J, Savani BN, Labopin M, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93(2):246–253. doi:10.1002/ajh.24963
   PubMed Web of Science ®Google Scholar
• Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843–850. doi:10.1182/blood-2014-03-563130
   PubMed Web of Science ®Google Scholar
• Marcoux C, Marin D, Ramdial J, et al. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol. 2023;98(5):712–719. doi:10.1002/ajh.26870
   PubMed Web of Science ®Google Scholar
• Mehta RS, Marin D, Alousi A, et al. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv. 2023;7(8):1594–1603. doi:10.1182/bloodadvances.2022009240
   PubMed Web of Science ®Google Scholar
• Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21(10):2145–2152. doi:10.1038/sj.leu.2404892
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Kärre K. In search of the ‘missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237–244. doi:10.1016/0167-5699(90)90097-S
   PubMedGoogle Scholar
• Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197–223. doi:10.1146/annurev.immunol.19.1.197
   PubMed Web of Science ®Google Scholar
• Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557–567. doi:10.1084/jem.20030788
   PubMed Web of Science ®Google Scholar
• Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immuno. 2002;20:217–251. doi:10.1146/annurev.immunol.20.092501.134942
   PubMed Web of Science ®Google Scholar
• Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644–650. doi:10.4049/jimmunol.172.1.644
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Al Malki MM, Kongtim P, et al. The European society for blood and marrow transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55(1):12–24. doi:10.1038/s41409-019-0499-z
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100. doi:10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010;16(4):533–542. doi:10.1016/j.bbmt.2009.11.022
   PubMed Web of Science ®Google Scholar
• Solomon SR, Aubrey MT, Zhang X, et al. Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables. Biol Blood Marrow Transplant. 2018;24(4):789–798. doi:10.1016/j.bbmt.2018.01.013
   PubMed Web of Science ®Google Scholar
• Wanquet A, Bramanti S, Harbi S, et al. Killer cell immunoglobulin-like receptor–ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell–replete haploidentical transplantation followed by post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2018;24(3):549–554. doi:10.1016/j.bbmt.2017.11.042
   PubMed Web of Science ®Google Scholar
• Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247–262. doi:10.1182/blood-2017-05-780668
   PubMed Web of Science ®Google Scholar
• Huang XJ, Zhao XY, Liu DH, et al. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia. 2007;21(4):848–851. doi:10.1038/sj.leu.2404566
   PubMed Web of Science ®Google Scholar
• Shimoni A, Labopin M, Lorentino F, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2019;33(1):230–239. doi:10.1038/s41375-018-0170-5
   PubMed Web of Science ®Google Scholar
• Schetelig J, Baldauf H, Koster L, et al. Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients With myelodysplastic syndromes or secondary acute myeloid leukemia. Front Immunol. 2021;11:584520.doi:10.3389/fimmu.2020.584520.
   PubMed Web of Science ®Google Scholar
• Meybodi MA, Cao W, Luznik L, et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019;3(17):2581–2585. doi:10.1182/bloodadvances.2019000614
   PubMedGoogle Scholar
• Ambinder A, Jain T, Tsai H-L, et al. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv. 2022;6(14):4335–4346. doi:10.1182/bloodadvances.2022007741
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Maruya E, Taniguchi K, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012;47(4):508–515. doi:10.1038/bmt.2011.131
   PubMed Web of Science ®Google Scholar
• Huang Y, Luo C, Wu G, et al. Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation – a systematic review and meta-analysis. Bone Marrow Transplant. 2023;58(5):544–551. doi:10.1038/s41409-023-01932-6
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Al Malki MM, Kongtim P, et al. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021;5(20):4031–4043. doi:10.1182/bloodadvances.2021004862
   PubMed Web of Science ®Google Scholar
• Mondragão-Rodrigues I, Macedo MF. Buffy coat processing impacts on monocytes’ capacity to present lipid antigens. Biomedicines. 2023;11(3):833.doi:10.3390/biomedicines11030833.
   PubMed Web of Science ®Google Scholar
• Touraine JL, Bétuel H, Pouteil-Noble C, et al. HLA class II antigens: structure, function, and expression in immunodeficiencies, autoimmune diseases, and allograft rejection. Adv Nephrol Necker Hosp. 1989;18:325–334.
   PubMedGoogle Scholar
• Bailén R, Vicario JL, Solán L, et al. Management of donor-specific antibodies in haploidentical transplant: multicenter experience from the Madrid group of hematopoietic transplant. Front Immunol. 2021;12:674658. doi:10.3389/fimmu.2021.674658
   PubMed Web of Science ®Google Scholar
• Santoro N, Mooyaart JE, Devillier R, et al. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: a study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transplant. 2023;58(1):54–60. doi:10.1038/s41409-022-01839-8
   PubMed Web of Science ®Google Scholar
• Zeis M, Uharek L, Glass B, et al. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br J Haematol. 1997;96(4):757–761. doi:10.1046/j.1365-2141.1997.d01-2101.x
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333–339. doi:10.1182/blood.V94.1.333.413a31_333_339
   PubMed Web of Science ®Google Scholar
• Brehm C, Huenecke S, Quaiser A, et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One. 2011;6(11):e27351. doi:10.1371/journal.pone.0027351
   PubMed Web of Science ®Google Scholar
• Boissel L, Tuncer HH, Betancur M, et al. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant. 2008;14(9):1031–1038. doi:10.1016/j.bbmt.2008.06.016
   PubMed Web of Science ®Google Scholar
• Somanchi SS, Senyukov VV, Denman CJ, et al. Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp. 2011;48:2540.doi:10.3791/2540.
   Google Scholar
• Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant. 2014;20(5):696–704. doi:10.1016/j.bbmt.2014.01.031
   PubMed Web of Science ®Google Scholar
• Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cell infusion after human leukocyte antigen-haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2016;22(11):2065–2076. doi:10.1016/j.bbmt.2016.08.008
   PubMed Web of Science ®Google Scholar
• Jaiswal SR, Zaman S, Nedunchezhian M, et al. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study. Cytotherapy. 2017;19(4):531–542. doi:10.1016/j.jcyt.2016.12.006
   PubMed Web of Science ®Google Scholar
• Stern M, Passweg JR, Meyer-Monard S, et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant. 2013;48(3):433–438. doi:10.1038/bmt.2012.162
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857–1868. doi:10.1182/blood-2017-05-785659
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Kongtim P, Soebbing D, et al. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022;36(1):155–164. doi:10.1038/s41375-021-01349-4
   PubMed Web of Science ®Google Scholar
• Dunbar EM, Buzzeo MP, Levine JB, et al. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica. 2008;93(12):1852–1858. doi:10.3324/haematol.13033
   PubMed Web of Science ®Google Scholar
• Lee K-H, Yoon SR, Gong J-R, et al. The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients – a randomized trial. Leukemia. 2023;37(4):807–819. doi:10.1038/s41375-023-01849-5
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Singh H, Huls MH, et al. Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126(9):3363–3376. doi:10.1172/JCI86721
   PubMed Web of Science ®Google Scholar
• Jain T, Sauter CS, Shah GL, et al. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/refractory B cell non-Hodgkin lymphoma. Leukemia. 2019;33(10):2540–2544. doi:10.1038/s41375-019-0476-y
   PubMed Web of Science ®Google Scholar
• Schubert ML, Dietrich S, Stilgenbauer S, et al. Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(9):1575–1580. doi:10.1016/j.bbmt.2020.04.025
   PubMed Web of Science ®Google Scholar
• Lutfi F, Holtzman N, Siglin J, et al. Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma. Br J Haematol. 2021;192(1):212–216. doi:10.1111/bjh.17121
   PubMed Web of Science ®Google Scholar